Targetable ERBB2 mutation status is an independent marker of adverse prognosis in estrogen receptor positive, ERBB2 non-amplified primary lobular breast carcinoma: a retrospective in silico analysis of public datasets
Sasagu Kurozumi, Mansour Alsaleem, Cíntia J. Monteiro, Kartikeya Bhardwaj, Stacey E. P. Joosten, Takaaki Fujii, Ken Shirabe, Andrew R. Green, Ian O. Ellis, Emad A. Rakha, Nigel P. Mongan, View ORCID ProfileDavid M. Heery, Wilbert Zwart, Steffi Oesterreich, Simon J. Johnston
doi: https://doi.org/10.1101/2020.01.24.20018622
